Karyopharm Therapeutics (KPTI) PT Raised to $35 at Baird
Tweet Send to a Friend
Baird analyst Michael Ulz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $35.00 (from $25.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
